FEATURED COMPANIES
- AbbVie Inc.
- Aurobindo Pharma
- Bristol-Myers Squibb
- F. Hoffmann-La Roche Ltd.
- Merck & Co.Inc.
- Ranbaxy Laboratories
Pharmaceutical API Manufacturing Global Market Report 2021: COVID-19 Growth and Change to 2030 provides strategists, marketers and senior management with the critical information they need to assess the global pharmaceutical api manufacturing market.
The report focuses on the pharmaceutical api manufacturing market which is experiencing strong growth. The report gives a guide to the pharmaceutical api manufacturing market which will be shaping and changing our lives over the next ten years and beyond, including the market's response to the challenge of the global pandemic.
Where is the largest and fastest growing market for pharmaceutical api manufacturing? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Pharmaceutical API Manufacturing Market Global report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
Teva Pharmaceutical Industries Ltd.; Sun Pharmaceutical Industries Ltd.; Boehringer Ingelheim; Pfizer; Aurobindo Pharma
Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA
Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Five years historic and ten years forecast.
Country and regional historic and forecast data, market share of competitors, market segments.
Data and analysis throughout the report is sourced using end notes.
This product will be delivered within 1-3 business days.
The report focuses on the pharmaceutical api manufacturing market which is experiencing strong growth. The report gives a guide to the pharmaceutical api manufacturing market which will be shaping and changing our lives over the next ten years and beyond, including the market's response to the challenge of the global pandemic.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Description:
Where is the largest and fastest growing market for pharmaceutical api manufacturing? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Pharmaceutical API Manufacturing Market Global report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The Market Characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, the impact of the COVID-19 virus and forecasting its recovery.
- Market segmentations break down market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the impact and recovery trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
- By Therapy Area: Cardiovascular disorders; Metabolic disorders; Neurological disorders; Oncology; Musculoskeletal disorders; NSAIDs; Other therapeutics uses
- By API Type: Chemical API; Biological API
- By Drug Type: Innovative Drugs; Generic Prescription; Over-the-counter (OTC) Drugs
Companies Mentioned:
Teva Pharmaceutical Industries Ltd.; Sun Pharmaceutical Industries Ltd.; Boehringer Ingelheim; Pfizer; Aurobindo Pharma
Countries:
Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA
Regions:
Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series:
Five years historic and ten years forecast.
Data Segmentations:
Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing:
Data and analysis throughout the report is sourced using end notes.
This product will be delivered within 1-3 business days.
Frequently Asked Questions about the Global Pharmaceutical API Manufacturing Market
What is the estimated value of the Global Pharmaceutical API Manufacturing Market?
What is the growth rate of the Global Pharmaceutical API Manufacturing Market?
What is the forecasted size of the Global Pharmaceutical API Manufacturing Market?
Who are the key companies in the Global Pharmaceutical API Manufacturing Market?
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- AbbVie Inc.
- Aurobindo Pharma
- Bristol-Myers Squibb
- F. Hoffmann-La Roche Ltd.
- Merck & Co.Inc.
- Ranbaxy Laboratories
1. Executive Summary2. Pharmaceutical API Manufacturing Market Characteristics3. Pharmaceutical API Manufacturing Market Trends and Strategies4. Impact Of COVID-19 On Pharmaceutical API Manufacturing28. Pharmaceutical API Manufacturing Pipeline Analysis29. Key Mergers and Acquisitions in the Pharmaceutical API Manufacturing Market30. Pharmaceutical API Manufacturing Market Future Outlook and Potential Analysis
5. Pharmaceutical API Manufacturing Market Size and Growth
6. Pharmaceutical API Manufacturing Market Segmentation
7. Pharmaceutical API Manufacturing Market Regional and Country Analysis
8. Asia-Pacific Pharmaceutical API Manufacturing Market
9. China Pharmaceutical API Manufacturing Market
10. India Pharmaceutical API Manufacturing Market
11. Japan Pharmaceutical API Manufacturing Market
12. Australia Pharmaceutical API Manufacturing Market
13. Indonesia Pharmaceutical API Manufacturing Market
14. South Korea Pharmaceutical API Manufacturing Market
15. Western Europe Pharmaceutical API Manufacturing Market
16. UK Pharmaceutical API Manufacturing Market
17. Germany Pharmaceutical API Manufacturing Market
18. France Pharmaceutical API Manufacturing Market
19. Eastern Europe Pharmaceutical API Manufacturing Market
20. Russia Pharmaceutical API Manufacturing Market
21. North America Pharmaceutical API Manufacturing Market
22. USA Pharmaceutical API Manufacturing Market
23. South America Pharmaceutical API Manufacturing Market
24. Brazil Pharmaceutical API Manufacturing Market
25. Middle East Pharmaceutical API Manufacturing Market
26. Africa Pharmaceutical API Manufacturing Market
27. Pharmaceutical API Manufacturing Market Competitive Landscape and Company Profiles
31. Appendix
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- AbbVie Inc.
- Aurobindo Pharma
- Bristol-Myers Squibb
- F. Hoffmann-La Roche Ltd.
- Merck & Co.Inc.
- Ranbaxy Laboratories
Major players in the pharmaceutical active pharmaceutical ingredients (API) manufacturing market are Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim), Pfizer, Inc. and Aurobindo Pharma.
The global pharmaceutical API manufacturing market is expected to grow from $170.06 billion in 2020 to $177.32 billion in 2021 at a compound annual growth rate (CAGR) of 4.3%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $215.9 billion in 2025 at a CAGR of 5%.
The pharmaceutical active pharmaceutical ingredients (API) manufacturing market consists of sales of pharmaceutical active pharmaceutical ingredients and related services. Active pharmaceutical ingredients are used to produce drugs which treat various diseases such as cardiovascular diseases, rare genetic disorders, infections, metabolic disorders, cancers, respiratory diseases and others. Active pharmaceutical ingredient is a chemical which is responsible for the pharmacological activity in the living body and are used as a major base for preparation of drugs.
The pharmaceutical API manufacturing market covered in this report is segmented by therapy area into cardiovascular disorders, metabolic disorders, neurological disorders, oncology, musculoskeletal disorders, NSAIDs, other therapeutics uses. It is also segmented by API type into chemical API, biological API and by drug type into innovative drugs, generic prescription, over-the-counter (OTC) drugs.
The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Stringent regulations for approval of pharmaceutical drugs acts as a restraint on the pharmaceutical API manufacturing market. Various regions have their own set of rules, guidelines, and regulations set by their respective drugs regulatory bodies. For example, in Japan, the manufacturers have to register an API with Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) through the country’s Drug Master File (DMF) system. Products like APIs and new excipients i.e. inactive substances used in a drug should be registered compulsorily. The API manufacturer is also responsible for DMF registration, even if they don't have their office in Japan. They should appoint an in-country caretaker (ICC) to apply on their behalf. Also, if there are any changes to be made to DMF products, either an application for change in registration or a minor change notification should be submitted by the ICC to the PMDA. This whole process delays the drugs approvals, thereby negatively affecting the pharmaceuticals API manufacturing market.
In January 2019, Bristol-Myers Squibb, a US-based company that discovers and manufactures biopharmaceutical products and drugs for cancer and other diseases acquired Celgene Corporation for $74 billion. With this acquisition, Bristol-Myers Squibb led to develop more innovative medicines and also result in a wider portfolio. Celgene Corporation, a US-based company that discovers, develops and commercializes medicines for cancer and inflammatory disorders.
The rise in aging population is one of the major drivers of the pharmaceutical API manufacturing market. As the aging population increases, the demand for pharmaceutical drugs also increases. API acts as a specialty drug in these medicines to cure a particular disease. For instance, in 2019, number of people over the age of 65 were 703 million, in 2050, the number of elderly people is expected to double to 1.5 billion. This led to increase demand for pharmaceutical drugs, significantly impacting the pharmaceutical API manufacturing market growth.
Many companies use modern technologies such as process control, and powder handling to optimize API manufacturing. These technologies include advances in Lyophilization i.e. freeze-drying process. It is a low-temperature dehydration process which involves freezing the product, lowering pressure and then removing the ice formed. For instance, Telstar, a company that manufactures efficient integrated systems for pharmaceutical and manufacturing processes, developed LyoGistics Zero, an automatic loading and unloading system for freeze dryers to manufacture hazardous products. The system uses a linear magnetic driving mechanism which functions without racks and belts to reduce particle generation and this improves the hygiene in API manufacturing. Also, ILC Dover, a pharmaceutical company, developed JetBreaker system, a semi-automatic powder handling system that separates powdered media and buffers powders so that they can be mixed better in a solution.
The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
The global pharmaceutical API manufacturing market is expected to grow from $170.06 billion in 2020 to $177.32 billion in 2021 at a compound annual growth rate (CAGR) of 4.3%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $215.9 billion in 2025 at a CAGR of 5%.
The pharmaceutical active pharmaceutical ingredients (API) manufacturing market consists of sales of pharmaceutical active pharmaceutical ingredients and related services. Active pharmaceutical ingredients are used to produce drugs which treat various diseases such as cardiovascular diseases, rare genetic disorders, infections, metabolic disorders, cancers, respiratory diseases and others. Active pharmaceutical ingredient is a chemical which is responsible for the pharmacological activity in the living body and are used as a major base for preparation of drugs.
The pharmaceutical API manufacturing market covered in this report is segmented by therapy area into cardiovascular disorders, metabolic disorders, neurological disorders, oncology, musculoskeletal disorders, NSAIDs, other therapeutics uses. It is also segmented by API type into chemical API, biological API and by drug type into innovative drugs, generic prescription, over-the-counter (OTC) drugs.
The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Stringent regulations for approval of pharmaceutical drugs acts as a restraint on the pharmaceutical API manufacturing market. Various regions have their own set of rules, guidelines, and regulations set by their respective drugs regulatory bodies. For example, in Japan, the manufacturers have to register an API with Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) through the country’s Drug Master File (DMF) system. Products like APIs and new excipients i.e. inactive substances used in a drug should be registered compulsorily. The API manufacturer is also responsible for DMF registration, even if they don't have their office in Japan. They should appoint an in-country caretaker (ICC) to apply on their behalf. Also, if there are any changes to be made to DMF products, either an application for change in registration or a minor change notification should be submitted by the ICC to the PMDA. This whole process delays the drugs approvals, thereby negatively affecting the pharmaceuticals API manufacturing market.
In January 2019, Bristol-Myers Squibb, a US-based company that discovers and manufactures biopharmaceutical products and drugs for cancer and other diseases acquired Celgene Corporation for $74 billion. With this acquisition, Bristol-Myers Squibb led to develop more innovative medicines and also result in a wider portfolio. Celgene Corporation, a US-based company that discovers, develops and commercializes medicines for cancer and inflammatory disorders.
The rise in aging population is one of the major drivers of the pharmaceutical API manufacturing market. As the aging population increases, the demand for pharmaceutical drugs also increases. API acts as a specialty drug in these medicines to cure a particular disease. For instance, in 2019, number of people over the age of 65 were 703 million, in 2050, the number of elderly people is expected to double to 1.5 billion. This led to increase demand for pharmaceutical drugs, significantly impacting the pharmaceutical API manufacturing market growth.
Many companies use modern technologies such as process control, and powder handling to optimize API manufacturing. These technologies include advances in Lyophilization i.e. freeze-drying process. It is a low-temperature dehydration process which involves freezing the product, lowering pressure and then removing the ice formed. For instance, Telstar, a company that manufactures efficient integrated systems for pharmaceutical and manufacturing processes, developed LyoGistics Zero, an automatic loading and unloading system for freeze dryers to manufacture hazardous products. The system uses a linear magnetic driving mechanism which functions without racks and belts to reduce particle generation and this improves the hygiene in API manufacturing. Also, ILC Dover, a pharmaceutical company, developed JetBreaker system, a semi-automatic powder handling system that separates powdered media and buffers powders so that they can be mixed better in a solution.
The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
Note: Product cover images may vary from those shown
A selection of companies mentioned in this report includes:
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Ltd.
- Boehringer Ingelheim
- Pfizer Inc.
- Aurobindo Pharma
- Novartis AG
- Dr. Reddy's Laboratories
- Merck & Co.Inc.
- BASF SE
- Bayer Healthcare
- Mylan N.V.
- Albemarle Corporation
- Actavis plc
- Hospira Inc.
- Ranbaxy Laboratories
- Virbac
- Zoetis
- Heska Co.
- AbbVie Inc.
- AstraZeneca plc
- Eli Lilly and Company
- GlaxoSmithKline plc
- Sanofi
- Bristol-Myers Squibb
- CiplaInc.
- F. Hoffmann-La Roche Ltd.
Note: Product cover images may vary from those shown
LOADING...